0001394548-17-000020.txt : 20170706
0001394548-17-000020.hdr.sgml : 20170706
20170706171916
ACCESSION NUMBER: 0001394548-17-000020
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170628
FILED AS OF DATE: 20170706
DATE AS OF CHANGE: 20170706
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Galena Biopharma, Inc.
CENTRAL INDEX KEY: 0001390478
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4640 SW MACADAM AVENUE
STREET 2: SUITE 270
CITY: PORTLAND
STATE: OR
ZIP: 97239
BUSINESS PHONE: 855 855 GALE
MAIL ADDRESS:
STREET 1: 4640 SW MACADAM AVENUE
STREET 2: SUITE 270
CITY: PORTLAND
STATE: OR
ZIP: 97239
FORMER COMPANY:
FORMER CONFORMED NAME: RXi Pharmaceuticals Corp
DATE OF NAME CHANGE: 20110926
FORMER COMPANY:
FORMER CONFORMED NAME: GALENA BIOPHARMA, INC.
DATE OF NAME CHANGE: 20110922
FORMER COMPANY:
FORMER CONFORMED NAME: RXI PHARMACEUTICALS CORP
DATE OF NAME CHANGE: 20110921
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Nisi Rudolph
CENTRAL INDEX KEY: 0001297775
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33958
FILM NUMBER: 17953208
MAIL ADDRESS:
STREET 1: TWO BALA PLAZA, SUITE 300
CITY: PHILADELPHIA
STATE: PA
ZIP: 19004
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0306
4
2017-06-28
0
0001390478
Galena Biopharma, Inc.
GALE
0001297775
Nisi Rudolph
C/O GALENA BIOPHARMA, INC.
2000 CROW CANYON PL., SUITE 380
SAN RAMON
CA
94583
1
0
0
0
Common Stock
2017-07-06
4
A
0
10924
0.59
A
25788
D
Stock Option (right to buy)
0.55
2017-06-08
4
A
0
5000
0
A
2027-06-08
Common Stock
5000
5000
D
Effective January 1, 2017, 33% of the cash retainer payments to our Board will be pain in unrestricted shares of the Company's common stock delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter.
Represents the closing stock price of the Company's stock on the first trading day of the quarter.
Granted pursuant to the Issuer's 2016 Incentive Plan.
This stock option will vest and become exercisable in equal quarterly installments over one year beginning three months from June 8, 2017, such that the option will be fully exercisable as of June 8, 2018.
Rudolph Nisi, M.D.
2017-07-06